Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Robinson, R. L.
Right arrow Articles by Hopkins, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, R. L.
Right arrow Articles by Hopkins, P. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 2001, Vol. 86, No. 2 166-168
© 2001 The Board of Management and Trustees of the British Journal of Anaesthesia

Editorial

Editorial III

A breakthrough in the genetic diagnosis of malignant hyperthermia

R. L. Robinson and P. M. Hopkins

The goal of a simple non-invasive DNA test for susceptibility to malignant hyperthermia (MH) has remained elusive. Given the complexity of the disorder at the genetic level, inherent with a genetically heterogeneous1 condition, the initial aim has been to introduce limited DNA testing for some families. This issue contains the first comprehensive description of the circumstances in which limited DNA testing may be introduced.2 This is in the form of guidelines produced by the European Malignant Hyperthermia Group (EMHG). It is, however, important to appreciate that these guidelines represent a consensus statement and not a validated process. In this editorial we examine the evidence underpinning the guidelines and the steps required for them to be validated.

For the last 30 yr the invasive in vitro muscle contracture test (IVCT) has been the only recognized diagnostic tool to assess MH status. A standardized European protocol was published in . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
F. Schuster, T. Metterlein, S. Negele, P. Kranke, R. M. Muellenbach, U. Schwemmer, N. Roewer, and M. Anetseder
An In-Vivo Metabolic Test for Detecting Malignant Hyperthermia Susceptibility in Humans: A Pilot Study
Anesth. Analg., September 1, 2008; 107(3): 909 - 914.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
R. R. Johi, R. Mills, P. J. Halsall, and P. M. Hopkins
Anaesthetic management of coronary artery bypass grafting in a patient with central core disease and susceptibility to malignant hyperthermia on statin therapy
Br. J. Anaesth., November 1, 2003; 91(5): 744 - 747.
[Abstract] [Full Text] [PDF]